Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Other Accumulated Expenses (2023 - 2025)

Zenas BioPharma has reported Other Accumulated Expenses over the past 3 years, most recently at $870000.0 for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $870000.0 for Q4 2025, up 249.4% from a year ago — trailing twelve months through Dec 2025 was $870000.0 (up 249.4% YoY), and the annual figure for FY2025 was $870000.0, up 249.4%.
  • Other Accumulated Expenses for Q4 2025 was $870000.0 at Zenas BioPharma, up from $580000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for ZBIO hit a ceiling of $870000.0 in Q4 2025 and a floor of $106000.0 in Q4 2023.
  • Median Other Accumulated Expenses over the past 3 years was $384000.0 (2025), compared with a mean of $432714.3.
  • Peak annual rise in Other Accumulated Expenses hit 249.4% in 2025, while the deepest fall reached 74.7% in 2025.
  • Zenas BioPharma's Other Accumulated Expenses stood at $106000.0 in 2023, then soared by 134.91% to $249000.0 in 2024, then soared by 249.4% to $870000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $870000.0 (Q4 2025), $580000.0 (Q3 2025), and $508000.0 (Q2 2025) per Business Quant data.